论文部分内容阅读
目的观察麻桔喘咳方对肺心病大鼠模型内皮素(ET-1)、一氧化氮(NO)及肺动脉血管的影响,探讨以宣肺平喘法所立的麻桔喘咳方治疗肺心病的作用机制。方法 SD大鼠56只,随机分为7组:麻桔喘咳方高、中、低剂量组、肺力咳组、卡托普利组、模型组和正常组。用野百合碱造成肺心病大鼠模型,麻桔喘咳方高、中、低剂量组分别给中药剂量合生药量12、6、3 g/kg,肺力咳组给药1.08 g/kg,卡托普利组给药0.01 g/kg。14 d后,检测血中NO、ET-1含量;计算各组右心肥厚指数、肺动脉面积、肺动脉血管壁面积;观察肺动脉形态。结果麻桔喘咳方高、中、低剂量能显著降低ET-1含量,而中、低剂量能显著增加NO含量,因此能明显改善野百合碱致肺心病模型大鼠血中ET-1/NO失衡(P<0.05或P<0.01)。与模型组相比,仅小剂量组能显著减小肺动脉血管壁面积和血管腔面积(P<0.01)。对右心肥厚指数则麻桔喘咳方无明显作用。病理组织学检查结果显示麻桔喘咳方能不同程度降低肺动脉血管壁厚度、增加血管腔面积(P<0.01)。结论麻桔喘咳方可能通过缓解ET-1/NO失衡,减轻右心肥厚和肺血管增生重构,而具有缓解肺心病急性发作期症状的功效。
Objective To observe the effect of Maoganchhikang on endothelin (ET-1), nitric oxide (NO) and pulmonary artery in a rat model of pulmonary heart disease (CHD) Heart disease mechanism of action. Methods Fifty-six SD rats were randomly divided into seven groups: high, medium and low dose group of Hendanchuanke prescription, Pulmonary cough group, captopril group, model group and normal group. The rat model of pulmonary heart disease was induced by monocrotaline. The high dose, middle dose and low dose of hematine and asthma cough were given to the rats in the dosage of 12,6 and 3 g / kg, Captopril group was given 0.01 g / kg. After 14 days, the contents of NO and ET-1 in the blood were measured. The right ventricular hypertrophy index, pulmonary artery area and pulmonary artery wall area were calculated. The pulmonary artery morphology was observed. Results High, medium and low doses of hematine and asthma can significantly reduce ET-1 content, and medium and low doses can significantly increase the content of NO, which can significantly improve the monocrotaline-induced pulmonary heart disease rat model of ET-1 / NO imbalance (P <0.05 or P <0.01). Compared with the model group, only the low dose group can significantly reduce the pulmonary artery wall area and lumen area (P <0.01). Right ventricular hypertrophy index cough orange cough side no significant effect. Histopathological examination showed that CZT could reduce pulmonary artery wall thickness and increase lumen area (P <0.01). Conclusions Hendanchuanke can alleviate the imbalance of ET-1 / NO and relieve right ventricular hypertrophy and remodeling of right heart, which can relieve the symptoms of acute episode of pulmonary heart disease.